| Trial ID: | L0625 |
| Source ID: | NCT02210715
|
| Associated Drug: |
Raltegravir
|
| Title: |
Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
HIV;Fatty Liver;Nonalcoholic Steatohepatitis;HIV;Fatty Liver;Nonalcoholic Steatohepatitis;HIV;Fatty Liver;Nonalcoholic Steatohepatitis;HIV;Fatty Liver;Nonalcoholic Steatohepatitis
|
| Interventions: |
Drug: Isentress.;Other: Continue usual antiretroviral therapy;Drug: Isentress.;Other: Continue usual antiretroviral therapy;Drug: Isentress.;Other: Continue usual antiretroviral therapy;Drug: Isentress.;Other: Continue usual antiretroviral therapy
|
| Outcome Measures: |
improvement of fatty liver or liver fibrosis;improvement of fatty liver or liver fibrosis;improvement of fatty liver or liver fibrosisDifference in serum CK-18 levels;Difference in transaminases levels;Difference in metabolic markers
|
| Sponsor/Collaborators: |
McGill University Health Center
|
| Gender: |
All
|
| Age: |
18 Yearsnan
|
| Phases: |
Phase 4
|
| Enrollment: |
58
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Screening. Masking: None (Open Label).
|
| Start Date: |
05/08/2014
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
16 December 2017
|
| Locations: |
Canada;Canada;Canada;Canada;Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT02210715
|
